Nucleai

Company Overview

Snapshot

Founded in July 2017 by Avi Veidman, Eliron Amir, and Lotan Chorev, Nucleai operates with 51–200 employees. The company has raised $60.5M across 4 funding rounds from 11 investors.

Business overview

Nucleai develops a spatial biology software platform that utilizes intelligence-grade geospatial AI to analyze and interpret complex cellular interactions within patient biopsies. This technology translates intricate biological data into actionable insights, accelerating the development of life-saving treatments and diagnostics. The platform offers an AI-driven spatial biomarker analysis solution, ingesting images from various modalities like H&E, IHC, and multiplex immunofluorescence to conduct advanced spatial analysis. Nucleai serves the biopharma industry, working with a significant portion of top biopharma companies, and partners across diagnostics, contract research organizations (CROs), and life sciences tools companies, operating within the Health Tech & Life Sciences sector.

Strategic signal

In June 2024, Nucleai announced a workforce optimization, laying off 15% of its employees. This strategic adjustment signals a recalibration of operational focus and resource allocation, likely aimed at streamlining the company's path to profitability and efficiency in a competitive market, which could be a critical inflection point for investors assessing its future trajectory.

Company Intelligence Q&A

What was a significant recent operational change at Nucleai?

In June 2024, Nucleai implemented a workforce optimization, resulting in the layoff of 15% of its employees. This indicates a strategic restructuring to enhance operational efficiency.

Which companies did Nucleai partner with in June 2024?

In June 2024, Nucleai partnered with Proscia to integrate predictive biomarker solutions, aiming to enhance digital pathology offerings.

When did Nucleai last raise a funding round and who led it?

The round was led by M Ventures, with participation from Debiopharm Innovation Fund.

What was Nucleai's collaboration with GoPath Diagnostics in April 2024?

In April 2024, Nucleai and GoPath Diagnostics announced a strategic collaboration to provide integrated AI-powered digital pathology solutions for clinical research and diagnostic applications.

What was the nature of the partnership between Lunaphore and Nucleai in September 2022?

In September 2022, Lunaphore and Nucleai announced a partnership to provide AI-powered spatial biology analysis, aiming to accelerate drug development.